Dianthus Reports Strong 75% Response Rate in Claseprubart Phase 3 CIDP Interim Analysis
DNTH has more than doubled off its 52-week low of $16.635.
Summary
Dianthus Therapeutics announced positive interim data from Part A of its Phase 3 CAPTIVATE trial for claseprubart in CIDP, showing a 75% response rate and leading to a streamlined Part B trial design.
Key Events · Product Development and Regulatory · DNTH
-
Strong Interim Phase 3 Data
75% of the first 40 patients in Part A of the CAPTIVATE trial for claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) achieved a confirmed response.
-
Clinically Meaningful Improvements
Confirmed responders showed significant improvements across multiple efficacy measures, including INCAT, Grip Strength, MRC-SS, and I-RODS, compared to non-responders.
-
Streamlined Trial Design
The Phase 3 CAPTIVATE trial's Part B will now enroll fewer patients (128 down from 192) with a 1:1 randomization, reflecting a higher conservative minimum responder rate of 50%.
-
Favorable Safety Profile
Claseprubart was generally well tolerated with no related serious infections, clinical symptoms of autoimmune activation or Drug-Induced Lupus (DIL), or discontinuations due to safety.
Analysis · DNTH · Life Sciences
This 8-K provides crucial new clinical data supporting the previously announced "GO decision" for the Phase 3 CAPTIVATE trial of claseprubart in CIDP. The 75% response rate from the interim analysis is a strong positive signal for the lead candidate, demonstrating significant efficacy and a favorable safety profile. The subsequent reduction in patient enrollment for Part B indicates increased confidence in the drug's performance and could accelerate the trial's completion, potentially bringing the drug to market faster. This de-risks a key pipeline asset and could significantly impact the company's valuation.
At the time of this filing, DNTH was trading at $76.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $16.64 to $96.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.